BiotechTube

V160

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cytomegalovirus Infections

Conditions

Cytomegalovirus Infections

Trial Timeline

Mar 8, 2019 → Nov 7, 2019

NCT ID
NCT03840174

About V160

V160 is a phase 1 stage product being developed by Merck for Cytomegalovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03840174. Target conditions include Cytomegalovirus Infections.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03840174Phase 1Completed

Competing Products

20 competing products in Cytomegalovirus Infections

See all competitors
ProductCompanyStageHype Score
ASP0113 + PlaceboAstellas PharmaPhase 2
52
ASP0113 + PlaceboAstellas PharmaPhase 3
77
Letermovir oral granules + Letermovir tablet + Letermovir intravenousMerckPhase 2
52
Letermovir 240 mg Oral TabletMerckPhase 2
52
Letermovir tablet + Letermovir IVMerckPhase 3
77
LetermovirMerckPhase 1
33
LetermovirMerckApproved
85
Letermovir 480 MG [Prevymis]MerckPhase 2
52
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose IDMerckPhase 1
33
GanciclovirMerckPre-clinical
23
Letermovir + PlaceboMerckPhase 3
77
LetermovirMerckPhase 2
52
V160 + PlaceboMerckPhase 2
52
LetermovirMerckPhase 3
77
LetermovirMerckPhase 3
77
Valganciclovir + GanciclovirRochePhase 3
77
Zidovudine + Didanosine + GanciclovirRochePhase 1
33
ValganciclovirRochePre-clinical
23
Foscarnet sodium + GanciclovirRochePhase 1
33
Valganciclovir + ValganciclovirRochePhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85